Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | NK cells vs T-cells

Ulrike Koehl • 7 Feb 2022
CAR-T Meeting 2022
General CAR-T

Ulrike Koehl, MD, PhD, University of Leipzig, Leipzig, Germany, talks on the uses and advantages of natural killer (NK) cells over T-cells. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Disclosures

Cooperation: Novartis, Miltenyi Biotec
Consulting: AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna

More from Ulrike Koehl

0:46
Scaling up CAR-T manufacturing with automation and digitalization
Ulrike Koehl • 7 Feb 2022
0:56
Minimizing the costs of CAR-T manufacturing
Ulrike Koehl • 7 Feb 2022
0:49
Centralized vs decentralized manufacturing of CAR-T therapies
Ulrike Koehl • 7 Feb 2022
1:14
Optimizing NK cell manufacturing
Ulrike Koehl • 7 Feb 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals